CONCLUSION: This report demonstrates the potential of KMT to achieve comprehensive remission in severe, treatment-resistant psychiatric comorbidities. The findings emphasize the necessity for controlled clinical trials to verify optimal therapeutic ketone ranges and establish generalizability across clinical populations experiencing complex psychiatric comorbidities.
